
Overview
Background
Associate Professor Victoria Atkinson is both a Senior Medical Oncologist and a Principal Investigator for clinical trials in the adjuvant and metastatic setting at the Princess Alexandra Hospital and Greenslopes Private Hospital (in collaboration with Gallipoli Medical Research Foundation). Additionally, she is an Associate Professor with the University of Queensland, Clinical School of Medicine. Associate Professor Atkinson’s research interests are in the field of Oncology, and she has extensive experience in targeted-therapies and immunotherapies. Her main research interests are melanoma and gastro-intestinal oncology. Associate Professor Atkinson is passionate about trying to improve outcome for all patients with advanced melanoma as well as advanced gastro-intestinal cancers.
Associate Professor Atkinson has been involved in the clinical development of the current targeted and immunotherapies in melanoma over the past decade bringing these therapies into clinical practice. She has been involved in advocating for patient access to these therapies for patients in Queensland and Australia from guidelines through to reimbursement policies. These therapies have revolutionised the lives of patients and brought about the longest median overall survival for advanced melanoma. However there still remains significant work to be done in therapy resistant disease and she continues to work with therapies towards overcoming resistance.
In the past 5 years, Associate Professor Atkinson has been an Invited Speaker at 22 national and international meetings including Medical Oncology Group of Australia ASM Immunotherapy Symposium, New Zealand Society for Medical Oncology meeting and the Society for Melanoma Research congress. A/Prof Atkinson has published 82 publications, 31 oral abstracts and 65 posters. Associate Professor Atkinson is actively involved in the research supervision of her basic and advanced trainees, and resident medical officers who demonstrate interest in a project. She has supervised trainees to complete their research projects and supported 6 Australian research poster presentations, and 10 international research poster presentations.
She is passionate and motivated to continue to change practice by bringing clinically important and relevant trials to Queensland and to mentor trainees and junior consultants to continue this tradition.
Availability
- Professor Victoria Atkinson is:
- Available for supervision
Research interests
-
Oncology
-
Melanoma
-
Gastro-intestinal oncology
-
Patient outcomes
Works
Search Professor Victoria Atkinson’s works on UQ eSpace
2019
Conference Publication
Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma
Tie, Emilia Nan, Lai-Kwon, Julia Elizabeth, Na, Lumine, Rtshiladze, Michael Alexander, Bozzi, James, Read, Tavis, Atkinson, Victoria, Au-Yeung, George, Long, Georgina V., McArthur, Grant A., Sandhu, Shahneen Kaur, Saw, Robyn, Walpole, Euan Thomas, Menzies, Alexander M., Smithers, B. Mark and Gyorki, David E. (2019). Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma. Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL United States, 31 May - 4 June 2019. Alexandria, VA United States: American Society of Clinical Oncology.
2018
Journal Article
Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma
Hauschild, Axel, Dummer, Reinhard, Schadendorf, Dirk, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Haas, Tomas, Shilkrut, Mark, Gasal, Eduard, Kefford, Richard, Kirkwood, John M. and Long, Georgina V. (2018). Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma. Journal of Clinical Oncology, 36 (35), 3441-3449. doi: 10.1200/JCO.18.01219
2018
Conference Publication
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238)
Weber, Jeffrey S., Mandala, Mario, Del Vecchio, Michele, Gogas, Helen, Arance, Ana M., Cowey, C. Lance, Dalle, Stephane, Schenker, Michael, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Grob, Jean-Jacques, Butler, Marcus, Middleton, Mark R., Maio, Michele, Atkinson, Victoria, Dummer, Reinhard, de Pril, Veerle, Qureshi, Anila, Larkin, James and Ascierto, Paolo A. (2018). Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238). National-Cancer-Research-Institute (NCRI) Cancer Conference, Glasgow Scotland, Nov 04-06, 2018. LONDON: NATURE PUBLISHING GROUP.
2018
Conference Publication
CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma
Lipson, E. J., Long, G. V., Tawbi, H., Schadendorf, D., Atkinson, V. G., Maurer, M., Simonsen, K. L., Harbison, C. and Hodi, F. S. (2018). CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS.
2018
Conference Publication
ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma
Ascierto, P. A., Arenberger, P., Atkinson, V. G., Hansson, J., Kapiteijn, E., Loquai, C., Negrier, S., Shaw, H. M., Tarhini, A., Walker, J., Geib, J., Rahimian, S., Swann, S. and Diab, A. (2018). ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.062
2018
Conference Publication
CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma
Lipson, E. J., Long, G. V., Tawbi, H., Schadendorf, D., Atkinson, V. G., Maurer, M., Simonsen, K. L., Harbison, C. and Hodi, F. S. (2018). CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.058
2018
Conference Publication
Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial
Atkinson, V. G., Hauschild, A., Santinami, M., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Schadendorf, D., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M. and Long, G. V. (2018). Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.007
2018
Conference Publication
Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D plus T) or placebo (Pbo) in the COMBI-AD trial
Atkinson, V. G., Hauschild, A., Santinami, M., Mandala, M., Sileni, V. Chiarion, Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Schadendorf, D., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M. and Long, G. V. (2018). Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D plus T) or placebo (Pbo) in the COMBI-AD trial. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS.
2018
Conference Publication
Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial
Dummer, R., Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Sileni, V. Chiarion, Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Kirkwood, J. M. and Long, G. V. (2018). Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS.
2018
Conference Publication
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Chiarion-Sileni, V., Larkin, J., Robert, C., Schadendorf, D., Dasgupta, K., Shilkrut, M., Garrett, J., Brase, J. C., Kefford, R., Kirkwood, J. M. and Dummer, R. (2018). Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS.
2018
Conference Publication
Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial
Dummer, R., Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Kirkwood, J. M. and Long, G. V. (2018). Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.006
2018
Conference Publication
ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma
Ascierto, P. A., Arenberger, P., Atkinson, V. G., Hansson, J., Kapiteijn, E., Loquai, C., Negrier, S., Shaw, H. M., Tarhini, A., Walker, J., Geib, J., Rahimian, S., Swann, S. and Diab, A. (2018). ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS.
2018
Conference Publication
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Chiarion-Sileni, V., Larkin, J., Robert, C., Schadendorf, D., Dasgupta, K., Shilkrut, M., Garrett, J., Brase, J. C., Kefford, R., Kirkwood, J. M. and Dummer, R. (2018). Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19-23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy424.053
2018
Journal Article
Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation
Long, Georgina V., Atkinson, Victoria, Hong, Angela, McArthur, Grant A. and Menzies, Alexander M. (2018). Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation. Lancet Oncology, 19 (8), E367-E367. doi: 10.1016/S1470-2045(18)30508-4
2018
Journal Article
The changing paradigm of management in melanoma brain metastases
Ladwa, Rahul and Atkinson, Victoria (2018). The changing paradigm of management in melanoma brain metastases. Asia Pacific Journal of Clinical Oncology, 14 (6), 453-458. doi: 10.1111/ajco.12998
2018
Journal Article
Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus
Visser, Els, Edholm, David, Smithers, B. Mark, Thomson, Iain G., Burmeister, Bryan H., Walpole, Euan T., Gotley, David C., Joubert, Warren L., Atkinson, Victoria, Mai, Tao, Thomas, Janine M. and Barbour, Andrew P. (2018). Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus. Journal of Surgical Oncology, 117 (8), 1687-1696. doi: 10.1002/jso.25089
2018
Journal Article
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, Alexander M. M., Blank, Christian U., Mandala, Mario, Long, Georgina V., Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Lichinitser, Mikhail, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Maio, Michele, van den Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul, Ibrahim, Nageatte, Marreaud, Sandrine, van Akkooi, Alexander C. J., Suciu, Stefan and Robert, Caroline (2018). Adjuvant pembrolizumab versus placebo in resected stage III melanoma. The New England Journal of Medicine, 378 (19), 1789-1801. doi: 10.1056/NEJMoa1802357
2018
Journal Article
Focal regression of a primary melanoma, fading lentigines, and poliosis in metastatic melanoma treated with anti-PD-1
Thomas, S, Laino, A, Sturm, R, Nufer, K, Lambie, D, Shepherd, B, Atkinson, V, Adams, L, Soyer, H P and Schaider, H (2018). Focal regression of a primary melanoma, fading lentigines, and poliosis in metastatic melanoma treated with anti-PD-1. Journal of the European Academy of Dermatology and Venereology : JEADV, 32 (5), e176-e177. doi: 10.1111/jdv.14678
2018
Journal Article
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Long, Georgina V., Atkinson, Victoria, Lo, Serigne, Sandhu, Shahneen, Guminski, Alexander D., Brown, Michael P., Wilmott, James S., Edwards, Jarem, Gonzalez, Maria, Scolyer, Richard A., Menzies, Alexander M. and McArthur, Grant A. (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. The Lancet Oncology, 19 (5), 672-681. doi: 10.1016/S1470-2045(18)30139-6
2018
Journal Article
Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers
Hammerlindl, Heinz, Ravindran Menon, Dinoop, Hammerlindl, Sabrina, Emran, Abdullah Al, Torrano, Joachim, Sproesser, Katrin, Thakkar, Divya, Xiao, Min, Atkinson, Victoria G., Gabrielli, Brian, Haass, Nikolas K., Herlyn, Meenhard, Krepler, Clemens and Schaider, Helmut (2018). Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers. Clinical Cancer Research, 24 (5), 1090-1102. doi: 10.1158/1078-0432.CCR-16-2118
Supervision
Availability
- Professor Victoria Atkinson is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
For media enquiries about Professor Victoria Atkinson's areas of expertise, story ideas and help finding experts, contact our Media team: